Objectives To develop a robust phenotypic AST method with a correctly set breakpoint for pretomanid (Pa), the most recently approved anti-tuberculosis drug. Methods The Becton Dickinson Mycobacterial
To develop standardized protocols for rapid delamanid susceptibility testing (DST) using the colorimetric resazurin microtiter assay (REMA) and the semi-automated BACTEC⢠MGIT⢠960 system (MGIT) b
Mtb isolates of different lineages were selected to include both wild-type and drug-resistant strains. The aim of the study was to determine the minimum inhibitory concentrations (MICs) for Mtb of mer
Pyrazinamide (PZA) is one of the first-line agents used for the treatment of tuberculosis. However, current phenotypic PZA susceptibility testing in the BACTEC MGIT 960 system is unreliable and false
